Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of Multiple-Ascending Doses of ACT-1004-1239 in Healthy Subjects
NCT04286750Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing ACT-1004-1239 (Multiple Ascending Doses) with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent (serious) adverse events up to 6 weeks. Started Jul 2020; status: completed.
02
Drugs
ACT-1004-1239
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04286750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286750.